Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more
Pmv Pharmaceuticals Inc (PMVP) - Net Assets
Latest net assets as of December 2025: $104.71 Million USD
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has net assets worth $104.71 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($116.56 Million) and total liabilities ($11.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $104.71 Million |
| % of Total Assets | 89.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -66.06% |
| 10-Year Change | N/A |
| Growth Volatility | 10.89 |
Pmv Pharmaceuticals Inc - Net Assets Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual net assets of Pmv Pharmaceuticals Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $104.71 Million | -40.53% |
| 2024-12-31 | $176.08 Million | -21.98% |
| 2023-12-31 | $225.69 Million | -8.27% |
| 2022-12-31 | $246.03 Million | -20.27% |
| 2021-12-31 | $308.56 Million | -14.08% |
| 2020-12-31 | $359.12 Million | +609.58% |
| 2019-12-31 | $-70.47 Million | -52.74% |
| 2018-12-31 | $-46.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pmv Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39636600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $84.00K | 0.08% |
| Other Components | $551.08 Million | 526.28% |
| Total Equity | $104.71 Million | 100.00% |
Pmv Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PLAYWAY SA
WAR:PLW
|
$72.15 Million |
|
Arverne Group S.A.
F:5H1
|
$72.20 Million |
|
CNB Bank Shares Inc
OTCQX:CNBN
|
$72.23 Million |
|
Zeus Co.Ltd
KQ:079370
|
$72.25 Million |
|
AZKOYEN SA INH. EO 060
F:AKK
|
$72.11 Million |
|
Leo Systems
TWO:5410
|
$72.05 Million |
|
Ucore Rare Metals Inc
OTCQX:UURAF
|
$72.00 Million |
|
Major Cineplex Group Public Company Limited
F:MJG1
|
$72.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pmv Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 176,080,000 to 104,712,000, a change of -71,368,000 (-40.5%).
- Net loss of 77,742,000 reduced equity.
- Other comprehensive income decreased equity by 55,000.
- Other factors increased equity by 6,429,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-77.74 Million | -74.24% |
| Other Comprehensive Income | $-55.00K | -0.05% |
| Other Changes | $6.43 Million | +6.14% |
| Total Change | $- | -40.53% |
Book Value vs Market Value Analysis
This analysis compares Pmv Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.78x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-15.26 | $1.56 | x |
| 2019-12-31 | $-1.64 | $1.56 | x |
| 2020-12-31 | $8.02 | $1.56 | x |
| 2021-12-31 | $6.84 | $1.56 | x |
| 2022-12-31 | $5.40 | $1.56 | x |
| 2023-12-31 | $4.70 | $1.56 | x |
| 2024-12-31 | $3.41 | $1.56 | x |
| 2025-12-31 | $1.99 | $1.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pmv Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-74.24%) is below the historical average (-24.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.92 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.30 Million |
| 2020 | -9.59% | 0.00% | 0.00x | 1.02x | $-70.35 Million |
| 2021 | -18.75% | 0.00% | 0.00x | 1.07x | $-88.70 Million |
| 2022 | -29.80% | 0.00% | 0.00x | 1.10x | $-97.92 Million |
| 2023 | -30.56% | 0.00% | 0.00x | 1.12x | $-91.53 Million |
| 2024 | -33.34% | 0.00% | 0.00x | 1.09x | $-76.32 Million |
| 2025 | -74.24% | 0.00% | 0.00x | 1.11x | $-88.21 Million |
Industry Comparison
This section compares Pmv Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pmv Pharmaceuticals Inc (PMVP) | $104.71 Million | 0.00% | 0.11x | $72.13 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |